Caley Castelein - 14 May 2026 Form 4 Insider Report for Whitehawk Therapeutics, Inc. (WHWK)

Reporting relationship: Director
Issuer ticker: WHWK
Reported as of: 14 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 May 2026, 16:02:43 UTC
Prior SEC filing: 28 Oct 2025
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen Rodin, as Attorney-in-Fact

Key filing fact

Caley Castelein filed Form 4 for Whitehawk Therapeutics, Inc. (WHWK) on 18 May 2026.

Key facts

This page summarizes Caley Castelein's Form 4 filing for Whitehawk Therapeutics, Inc. (WHWK).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 May 2026, 16:02.

Change

Previous filing in this sequence was filed on 28 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001355758 Primary reporting owner

Castelein Caley

Relationship: Director
Address: C/O WHITEHAWK THERAPEUTICS, INC., 2 HEADQUARTERS PLAZA, EAST BUILDING, 11T, MORRISTOWN
Signature: /s/ Stephen Rodin, as Attorney-in-Fact
Signature date: 18 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

WHWK transaction

Common Stock

Award

Transaction value
Shares: +255,102
Change %: +1295%
Price: $3.92^*
Shares after: 274,796
Date: 14 May 2026
Ownership: Direct

WHWK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,165,998
Date: 14 May 2026
Ownership: See footnote
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

WHWK transaction Derivative

Pre-Funded Warrant (right to buy)

Award

Transaction value
Shares: +2,072,756
Change %
Price: $8124996.24^*
Shares after: 2,072,756
Date: 14 May 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 2,072,756
Exercise price: $0.000100
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Shares held by KVP Capital, LP. The Reporting Person is the Managing Director of KVP Capital. The Reporting Person disclaims beneficial ownership of shares held by KVP Capital, except to the extent of his pecuniary interest therein.

Footnote F2

Subject to the terms and conditions set forth in the Pre-Funded Warrant, the holder thereof may, at any time and from time to time on or after May 14, 2026, exercise the Pre-Funded Warrant until it has been exercised in full. Pursuant to the terms of the Pre-Funded Warrant, the holder cannot exercise any of the Pre-Funded Warrant to the extent the holder and its affiliates, including the Reporting Person, would beneficially own, after any such exercise, more than 4.99% of the outstanding Common Stock.

Footnote F3

Pre-Funded Warrant held by KVP Capital, LP. The Reporting Person is the Managing Director of KVP Capital. The Reporting Person disclaims beneficial ownership of the Pre-Funded Warrant held by KVP Capital, except to the extent of his pecuniary interest therein.